374 related articles for article (PubMed ID: 18372677)
1. Therapeutic interventions for autosomal dominant polycystic kidney disease.
Edelstein CL
Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
[TBL] [Abstract][Full Text] [Related]
2. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
[TBL] [Abstract][Full Text] [Related]
4. Optimal care of autosomal dominant polycystic kidney disease patients.
Schrier RW
Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
[TBL] [Abstract][Full Text] [Related]
5. [New therapies for ADPKD].
Rathaus M
G Ital Nefrol; 2007; 24(6):526-34. PubMed ID: 18278756
[TBL] [Abstract][Full Text] [Related]
6. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
7. Role of vasopressin antagonists.
Torres VE
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
Wüthrich RP; Serra AL
Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
[TBL] [Abstract][Full Text] [Related]
9. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
Wüthrich RP; Serra AL; Kistler AD
Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
11. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
13. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
Cadnapaphornchai MA; Fick-Brosnahan GM; Duley I; Johnson AM; Strain JD; DeGroff CG; Schrier RW
Contemp Clin Trials; 2005 Apr; 26(2):211-22. PubMed ID: 15837441
[TBL] [Abstract][Full Text] [Related]
14. Management of ESRD in patients with autosomal dominant polycystic kidney disease.
Alam A; Perrone RD
Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619
[TBL] [Abstract][Full Text] [Related]
15. Review of tolvaptan for autosomal dominant polycystic kidney disease.
Baur BP; Meaney CJ
Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
[TBL] [Abstract][Full Text] [Related]
16. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
Rapoport J
QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
[No Abstract] [Full Text] [Related]
17. [Modern treatment of autosomal dominant polycystic kidney disease].
Wołyniec W; Jankowska MM; Rutkowski B
Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
[TBL] [Abstract][Full Text] [Related]
18. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.
Rysz J; Gluba-Brzózka A; Franczyk B; Banach M; Bartnicki P
Expert Opin Pharmacother; 2016 Oct; 17(15):2049-56. PubMed ID: 27650472
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of autosomal dominant polycystic kidney disease.
Bennett WM; Elzinga LW
Kidney Int Suppl; 1993 Jul; 42():S74-9. PubMed ID: 8361135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
